<DOC>
	<DOCNO>NCT01802658</DOCNO>
	<brief_summary>Subjects lesion bone marrow risk fracture fragility bone . The median time onset fracture 8.5 year . Fracture increase cost care , dependency . Bone fragility secondary hormonal disorder calcium phosphate , impaired excretion neuropeptides , vasomotor symptom associate asset promote bone loss architectural disorganization . These phenomenon occur first week development spinal cord injury predominate distal femur proximal tibia . From third year , demineralization stabilizes , bone mass estimate 70 50 % initial bone mass , new equilibrium . No clinical evidence predictive fracture risk . A criteria surrogate must use ass risk . There association bone mineral density fracture risk . The fracture threshold knee evaluate 0.87 g/cm2 . Evaluation bone mineral density distal femur predictor fracture risk . Measure reliable reproducible , easy perform , good element monitor efficacy anti-resorptive therapy .</brief_summary>
	<brief_title>Bone Demineralization Lesions Injured Marrow : Efficacy Tolerability Administration Early Repeated Zoledronic Acid . Comparative Study , Prospective , Double-blind Controlled ( DBMZol )</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Demineralization , Pathologic</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Being diagnose spinal cord injury le 12 week etiology stable , level injury C5 L2 , AIS grade A D. Female male 18 45 year . No pregnancy . No osteoporosis . Good oral health . Good glomerular filtration . No consindication Zoledronic Acid . No drug affect bone metabolism pregnancy . osteoporosis . consindication Zoledronic Acid . drug affect bone metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bone marrow demineralization lesion , : efficacy tolerability , zoledronic acid</keyword>
</DOC>